GLP-1RAs, with results indicating that oral semaglutide (14 mg) is likely to be cost-effective versus dulaglutide, exenatide (once weekly and twice daily), liraglutide, and lixisenatide in terms of achieving glycemic control targets [74]
This multi-pathway approach supports appetite control while influencing how the body uses and stores energy
It is unknown whether MOUNJARO causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as human relevance of tirzepatide-induced rodent thyroid C-cell tumors has not been determined
The National Institutes of Health (NIH) emphasizes that nutritional adequacy is critical during medical weight management
Some patients have side effects with any additives and brand name formulations
Due to the long-acting nature of semaglutide, it provides a sustained drug effect